tetano
Editor, Senior Moderator
Hepatol Int. 2020 Apr 10. doi: 10.1007/s12072-020-10043-z. [Epub ahead of print]
Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation.
Liu H[SUP]1[/SUP], He X[SUP]1[/SUP], Wang Y[SUP]2[/SUP], Zhou S[SUP]1[/SUP], Zhang D[SUP]1[/SUP], Zhu J[SUP]3[/SUP], He Q[SUP]4[/SUP], Zhu Z[SUP]5[/SUP], Li G[SUP]6[/SUP], Sun L[SUP]6[/SUP], Wang J[SUP]7[/SUP], Cheng G[SUP]2[/SUP], Liu Z[SUP]8[/SUP], Lau G[SUP]9,[/SUP][SUP]10[/SUP].
Author information
Abstract
Annually, around 850 liver transplantation is performed in Beijing, China. Recently, the new coronavirus pneumonia (COVID-19) caused by 2019 novel coronavirus (2019-nCoV) has affected nearly 200 countries worldwide. 2019-nCov can cause severe lung disease, multiple-organ damage, and significant mortalities. Liver transplant recipients, because of long-term oral immunosuppressant effects, may be more susceptible to 2019-nCoV infection and have a worse prognosis than the general population. It is urgent to set up guidelines for the prevention, diagnosis, and treatment of COVID-19 in liver transplant recipients. In this article, we reviewed the clinical aspects of 2019-nCoV infection, characteristics of liver transplant recipients, immunosuppressant usage, and potential drug interactions to provide recommendations to clinical staff managing liver transplant recipients during the COVID-19 epidemic.
KEYWORDS:
2019-nCoV; COVID-19; Liver transplantation; Management
PMID:32277387DOI:10.1007/s12072-020-10043-z
Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation.
Liu H[SUP]1[/SUP], He X[SUP]1[/SUP], Wang Y[SUP]2[/SUP], Zhou S[SUP]1[/SUP], Zhang D[SUP]1[/SUP], Zhu J[SUP]3[/SUP], He Q[SUP]4[/SUP], Zhu Z[SUP]5[/SUP], Li G[SUP]6[/SUP], Sun L[SUP]6[/SUP], Wang J[SUP]7[/SUP], Cheng G[SUP]2[/SUP], Liu Z[SUP]8[/SUP], Lau G[SUP]9,[/SUP][SUP]10[/SUP].
Author information
Abstract
Annually, around 850 liver transplantation is performed in Beijing, China. Recently, the new coronavirus pneumonia (COVID-19) caused by 2019 novel coronavirus (2019-nCoV) has affected nearly 200 countries worldwide. 2019-nCov can cause severe lung disease, multiple-organ damage, and significant mortalities. Liver transplant recipients, because of long-term oral immunosuppressant effects, may be more susceptible to 2019-nCoV infection and have a worse prognosis than the general population. It is urgent to set up guidelines for the prevention, diagnosis, and treatment of COVID-19 in liver transplant recipients. In this article, we reviewed the clinical aspects of 2019-nCoV infection, characteristics of liver transplant recipients, immunosuppressant usage, and potential drug interactions to provide recommendations to clinical staff managing liver transplant recipients during the COVID-19 epidemic.
KEYWORDS:
2019-nCoV; COVID-19; Liver transplantation; Management
PMID:32277387DOI:10.1007/s12072-020-10043-z